TY - JOUR
T1 - Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours
T2 - updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
AU - Lawrence, N.
AU - Martin, A.
AU - Toner, G.
AU - Stockler, M.
AU - Buizen, L.
AU - Thomson, D.
AU - Gebski, V.
AU - Friedlander, M.
AU - Yeung, A.
AU - Wong, N.
AU - Gurney, H.
AU - Rosenthal, M.
AU - Singhal, N.
AU - Kichenadasse, G.
AU - Wong, S.
AU - Lewis, C.
AU - Vasey, P.
AU - Grimison, P.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.
AB - Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.
UR - http://www.scopus.com/inward/record.url?scp=85040925777&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdw313
DO - 10.1093/annonc/mdw313
M3 - Letter
C2 - 27502724
AN - SCOPUS:85040925777
VL - 27
SP - 2302
EP - 2303
JO - Annals of Oncology : Official Journal of the European Society for Medical Oncology
JF - Annals of Oncology : Official Journal of the European Society for Medical Oncology
SN - 0923-7534
IS - 12
ER -